← Back to Clinical Trials
Recruiting NCT06414317

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Locally Advanced Bladder Carcinoma
Sponsor Roswell Park Cancer Institute
Study Type INTERVENTIONAL
Phase N/A
Enrollment 160
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-01-12
Completion 2027-03-31
Interventions
Assessment of DistressConsultation VisitNutritional Assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally advanced), to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Patients with advanced bladder cancer tend to be older, have multiple medical conditions and often have poor access to health care. An ENST may be an effective method to improve participation in treatment decision-making and care planning among patients with locally advanced, metastatic and unresectable bladder cancer and their caregivers.

Eligibility Criteria

Inclusion Criteria: * PATIENTS: Age ≥ 18 years * PATIENTS: Metastatic or locally advanced, unresectable bladder cancer * PATIENTS: Receiving or planning to receive systemic therapy for bladder cancer at Roswell Park Comprehensive Cancer Center (RPCCC) * PATIENTS: Subjects can be enrolled any time from initial diagnosis of advanced disease to within 8 weeks after initiation of first-line systemic therapy for advanced bladder cancer * PATIENTS: Able to speak, understand, read, and write English * CAREGIVERS: Age ≥ 18 years * CAREGIVERS: Only caregivers of enrolled patients will be included in the study * CAREGIVERS: Should be able to speak, understand, read, and write English * CAREGIVERS: Caregivers will be enrolled in the study during the same time window as for patient enrollment (from initial visit to within 8 weeks of patients starting frontline therapy) Exclusion Criteria: * PATIENTS: Not receiving any form of systemic therapy for bladder cancer due to Eastern Cooperative Oncology

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}